Clinical characteristics, prognostic factors, and long-term outcomes associated with epithelial malignancies of the thymus: A 20-year single-institution experience.
thymic carcinoma
thymic epithelial tumors
thymoma
Journal
Cancer reports (Hoboken, N.J.)
ISSN: 2573-8348
Titre abrégé: Cancer Rep (Hoboken)
Pays: United States
ID NLM: 101747728
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
revised:
17
09
2022
received:
07
07
2022
accepted:
18
10
2022
pubmed:
13
11
2022
medline:
22
3
2023
entrez:
12
11
2022
Statut:
ppublish
Résumé
Thymic epithelial tumors are rare and include thymomas and thymic carcinomas. There is scarce literature characterizing prognostic factors and long-term outcomes in these tumors. This review aims to describe disease features of thymomas and thymic carcinomas and to report clinical differences among thymoma histological subtypes. A retrospective chart review was performed at the University of Florida Shands Hospital, a tertiary care academic medical center in Gainesville, Florida, USA. The review included clinical data of adults with thymic epithelial tumors diagnosed between 2001 and 2021. Significant associations among demographics, histology, stage, and outcomes were investigated. Thymoma subgroup analysis was performed using histological subtype and sex. Forty patients with thymoma and seven patients with thymic carcinoma were included in the final analysis. Among those with thymomas, patients with subtype B1, B2, or B3 tumors were younger, had larger tumors, and presented with higher stage disease when compared to those with subtypes A or AB. Tumor recurrence was most common in subtype B2 and B3 tumors (50.0% and 16.7% vs. 0%; p < .01). However, there was no significant difference in overall survival between histologic subtypes. Compared to females, males with thymomas had superior overall survival (103.0 vs. 62.9 months; p = .021) despite presenting with larger tumors (9.8 vs. 5.8 cm; p = .041). Concomitant myasthenia gravis was associated with increased recurrence but not worsened mortality. Compared to thymomas, patients with thymic carcinoma presented with higher-stage disease and had poorer 5-year survival (50.0% vs. 93.1%; p < .01). This study affirmed pathologic stage and resectability as prognostic factors for thymic epithelial tumors. New findings include inferior overall survival in female patients and higher recurrence rates in those with thymomas and concomitant myasthenia gravis.
Sections du résumé
BACKGROUND
Thymic epithelial tumors are rare and include thymomas and thymic carcinomas. There is scarce literature characterizing prognostic factors and long-term outcomes in these tumors.
AIMS
This review aims to describe disease features of thymomas and thymic carcinomas and to report clinical differences among thymoma histological subtypes.
METHODS AND RESULTS
A retrospective chart review was performed at the University of Florida Shands Hospital, a tertiary care academic medical center in Gainesville, Florida, USA. The review included clinical data of adults with thymic epithelial tumors diagnosed between 2001 and 2021. Significant associations among demographics, histology, stage, and outcomes were investigated. Thymoma subgroup analysis was performed using histological subtype and sex. Forty patients with thymoma and seven patients with thymic carcinoma were included in the final analysis. Among those with thymomas, patients with subtype B1, B2, or B3 tumors were younger, had larger tumors, and presented with higher stage disease when compared to those with subtypes A or AB. Tumor recurrence was most common in subtype B2 and B3 tumors (50.0% and 16.7% vs. 0%; p < .01). However, there was no significant difference in overall survival between histologic subtypes. Compared to females, males with thymomas had superior overall survival (103.0 vs. 62.9 months; p = .021) despite presenting with larger tumors (9.8 vs. 5.8 cm; p = .041). Concomitant myasthenia gravis was associated with increased recurrence but not worsened mortality. Compared to thymomas, patients with thymic carcinoma presented with higher-stage disease and had poorer 5-year survival (50.0% vs. 93.1%; p < .01).
CONCLUSION
This study affirmed pathologic stage and resectability as prognostic factors for thymic epithelial tumors. New findings include inferior overall survival in female patients and higher recurrence rates in those with thymomas and concomitant myasthenia gravis.
Identifiants
pubmed: 36369906
doi: 10.1002/cnr2.1750
pmc: PMC10026295
doi:
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1750Informations de copyright
© 2022 The Authors. Cancer Reports published by Wiley Periodicals LLC.
Références
J Thorac Oncol. 2016 Oct;11(10):1785-92
pubmed: 27346413
Neurology. 2001 Nov 13;57(9):1579-82
pubmed: 11706095
J Thorac Oncol. 2011 Jul;6(7 Suppl 3):S1691-7
pubmed: 21847049
Eur J Cardiothorac Surg. 2002 Feb;21(2):307-13
pubmed: 11825741
Int J Radiat Oncol Biol Phys. 1995 Jun 15;32(3):651-9
pubmed: 7790251
Lancet Oncol. 2018 Mar;19(3):347-355
pubmed: 29395863
Cell Rep Med. 2021 Sep 03;2(9):100392
pubmed: 34622229
J Thorac Oncol. 2011 Jul;6(7 Suppl 3):S1710-6
pubmed: 21847052
Asian J Surg. 2012 Oct;35(4):144-8
pubmed: 23063086
Ann Thorac Surg. 2010 Jan;89(1):245-52; discussion 252
pubmed: 20103246
J Thorac Oncol. 2014 May;9(5):596-611
pubmed: 24722150
Mod Pathol. 2010 Dec;23(12):1641-9
pubmed: 20834239
J Thorac Cardiovasc Surg. 2005 Nov;130(5):1413-21
pubmed: 16256797
Eur J Cancer. 2019 May;113:78-86
pubmed: 30991261
Cancer Rep (Hoboken). 2023 Mar;6(3):e1750
pubmed: 36369906
J Cardiothorac Surg. 2021 Jan 7;16(1):8
pubmed: 33413522
J Thorac Oncol. 2015 Feb;10(2):367-72
pubmed: 25616178
Ann Surg. 1996 Aug;224(2):219-24
pubmed: 8757387
Asian Cardiovasc Thorac Ann. 2012 Feb;20(1):48-52
pubmed: 22371942
J Thorac Oncol. 2017 Apr;12(4):734-744
pubmed: 28126540
Lung Cancer. 2005 Oct;50(1):59-66
pubmed: 16009453
Ann Thorac Surg. 2004 Apr;77(4):1183-8
pubmed: 15063231
Autoimmune Dis. 2011;2011:474512
pubmed: 21860784
Front Oncol. 2020 Nov 27;10:583489
pubmed: 33330060
Cancer Epidemiol. 2019 Aug;61:133-138
pubmed: 31254794
Int J Cancer. 2002 Apr 20;98(6):900-6
pubmed: 11948470
Asian Pac J Cancer Prev. 2020 Mar 01;21(3):653-661
pubmed: 32212790
Oncol Lett. 2016 Jun;11(6):4177-4182
pubmed: 27313762
Cancer. 2002 Feb 1;94(3):624-32
pubmed: 11857293
J Thorac Oncol. 2020 Mar;15(3):436-447
pubmed: 31783179
J Thorac Dis. 2020 Dec;12(12):7635-7641
pubmed: 33447455
Int J Cancer. 2003 Jul 1;105(4):546-51
pubmed: 12712448
Chest. 2005 Mar;127(3):755-61
pubmed: 15764754
Cell Mol Immunol. 2011 May;8(3):199-202
pubmed: 21317916
Cancer. 1998 Oct 15;83(8):1495-503
pubmed: 9781943
Mediastinum. 2019 Sep;3:
pubmed: 31608320
J Thorac Dis. 2021 Mar;13(3):1851-1863
pubmed: 33841973
Cancer. 2015 Apr 1;121(7):1008-16
pubmed: 25565590
Eur J Cardiothorac Surg. 2014 Sep;46(3):361-8
pubmed: 24482389
Eur J Cardiothorac Surg. 2004 Aug;26(2):412-8
pubmed: 15296907